Both Leqembi and another drug expected to be approved this year, Eli Lilly’s donanemab, work by clearing the amyloid plaque buildups in the brain associated with Alzheimer’s disease.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Leqembi, the first drug shown to slow Alzheimer’s, has been approved by the FDA, but most U.S. patients will not be able to receive treatment for months.

Eisai spokeswoman Libby Holman said prescriptions for Leqembi have been written, and that the company expects patients to begin receiving the drug soon. It will cost about $26,500 for a year of ...